(NASDAQ: HRTX) Heron Therapeutics's forecast annual revenue growth rate of 18.51% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Heron Therapeutics's revenue in 2026 is $154,904,000.On average, 5 Wall Street analysts forecast HRTX's revenue for 2026 to be $33,667,076,376, with the lowest HRTX revenue forecast at $31,964,586,037, and the highest HRTX revenue forecast at $35,158,405,121. On average, 4 Wall Street analysts forecast HRTX's revenue for 2027 to be $40,499,662,184, with the lowest HRTX revenue forecast at $35,586,384,420, and the highest HRTX revenue forecast at $45,254,568,754.
In 2028, HRTX is forecast to generate $48,874,481,765 in revenue, with the lowest revenue forecast at $39,096,945,892 and the highest revenue forecast at $58,736,859,349.